My Companies
Notification
Account
Log Out
Login
Gland Pharma signed an MSA with an unnamed global pharmaceutical company covering 55 sterile-injectable SKUs across three sites. Following two-year technology transfers, revenues are expected from 2029, with annualized potential of approximately USD 90–100 million once fully commercialized.
Gland Pharma Promoter Fosun Sells 6% Stake Via Open Market
Gland Pharma Promoter Fosun Sells 6% Stake In Open Market
Gland Pharma Schedules One-On-One Meeting With Kotak Mutual Fund
Gland Pharma Appoints Deepak Sapra From Dr Reddy’s As New CEO
Gland Pharma Schedules UTI, Ashmore And Motilal Oswal Investor Meetings